In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve clinical outcomes.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Davies, H. et al. Nature 417, 949–954 (2002).
Hyman, D. M. et al. N. Engl. J. Med. 373, 726–736 (2015).
Corcoran, R. B. et al. Cancer Discov. 2, 227–235 (2012).
Corcoran, R. B. et al. Cancer Discov. 8, 428–443 (2018).
Tian, J. Nat. Med. https://doi.org/10.1038/s41591-022-02181-8 (2022).
Kopetz, S. et al. N. Engl. J. Med. 381, 1632–1643 (2019).
Eng, C. et al. Lancet Oncol. 20, 849–861 (2019).
Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).
Andre, T. et al. J. Clin. Oncol. 38, LBA4 (2020). 18 suppl.
Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).
Elez, E. et al. Nat. Med. 28, 2162–2170 (2022).
Morris, V. K. et al. J. Clin. Oncol. 40, 12 (2022). 4 suppl.
E.E. has received personal speaker honoraria from Organon and Novartis; and personal advisory board honoraria from Amgen, Bayer, Hoffman-La Roche, Merck Serono, Sanofi, Pierre Fabre, MSD, and Servier. Educational collaboration with Imedex/HMP and PeerView Institute for Medical Education. J.R. has received personal speaker honoraria from Sanofi and AMGEN, and accommodation expenses from Pierre-Fabre, Servier, Amgen and Merck. J.T. reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. Stocks: Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER).
Rights and permissions
About this article
Cite this article
Elez, E., Ros, J. & Tabernero, J. Seeking therapeutic synergy in BRAF mutant colorectal cancer. Nat Med 29, 307–308 (2023). https://doi.org/10.1038/s41591-022-02192-5